Elicio Therapeutics (ELTX) Enterprise Value (2023 - 2026)

Elicio Therapeutics (ELTX) has reported Enterprise Value for 4 consecutive years, with $62.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Enterprise Value fell 39.94% year-over-year to $62.1 million; the trailing twelve-month figure through Jun 2026 stood at $62.1 million (down 39.94% YoY), and the FY2025 full-year result was $123.1 million, up 228.74% from the prior year.
• Enterprise Value fell to $62.1 million in Q2 2026 per ELTX's latest filing, from $184.3 million in the prior quarter.
• Across five years, Enterprise Value topped out at $184.3 million in Q1 2026 and bottomed at $7.8 million in Q2 2023.
• Historically, Enterprise Value has averaged $75.0 million across 4 years, with a median of $60.7 million in 2025.
• The sharpest annual moves came in 2024 and 2026: Enterprise Value soared 392.97% in 2024, then sank 39.94% in 2026.
• Over 4 years, Enterprise Value stood at $28.6 million in 2023, then jumped by 31.17% to $37.5 million in 2024, then jumped by 228.74% to $123.1 million in 2025, then slumped by 49.54% to $62.1 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered $62.1 million, $184.3 million, and $123.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.